Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Consensus Rating of “Moderate Buy” from Analysts

Kalaris Therapeutics Inc. (NASDAQ:KLRS) has earned an average rating of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $14.00.

KLRS has been the subject of several recent research reports. Wall Street Zen raised shares of Kalaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th. Citigroup reiterated an “outperform” rating on shares of Kalaris Therapeutics in a report on Thursday, December 18th. Citizens Jmp began coverage on Kalaris Therapeutics in a research note on Monday, November 3rd. They set a “market outperform” rating and a $20.00 target price for the company. Chardan Capital began coverage on Kalaris Therapeutics in a research report on Tuesday, December 23rd. They issued a “buy” rating and a $19.00 price target on the stock. Finally, Raymond James Financial initiated coverage on Kalaris Therapeutics in a research report on Tuesday, September 2nd. They set a “strong-buy” rating for the company.

Kalaris Therapeutics Price Performance

Shares of Kalaris Therapeutics stock opened at $9.13 on Tuesday. The stock has a market capitalization of $170.73 million, a price-to-earnings ratio of -2.42 and a beta of -0.04. The business has a 50-day moving average of $6.56 and a 200 day moving average of $4.63. Kalaris Therapeutics has a 12 month low of $2.14 and a 12 month high of $12.90.

Kalaris Therapeutics (NASDAQ:KLRS) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.02.

Institutional Investors Weigh In On Kalaris Therapeutics

Large investors have recently modified their holdings of the company. Johnson Financial Group Inc. acquired a new stake in shares of Kalaris Therapeutics in the 3rd quarter valued at $58,000. XTX Topco Ltd acquired a new stake in Kalaris Therapeutics in the second quarter valued at $65,000. Bridgeway Capital Management LLC purchased a new stake in Kalaris Therapeutics during the 3rd quarter worth about $130,000. Belpointe Asset Management LLC acquired a new position in shares of Kalaris Therapeutics during the 3rd quarter worth about $231,000. Finally, Fortis Capital Advisors LLC purchased a new position in shares of Kalaris Therapeutics in the 3rd quarter valued at about $231,000. 66.05% of the stock is owned by hedge funds and other institutional investors.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.